
EpitogenX is a biotech company developing innovative platforms for immunoassay, vaccine, and antibody development using artificial intelligence. Their core technologies, EpitoGen® and AI EpitoPrediktTM, are designed to revolutionize diagnostics, vaccine design, biotherapeutics, and antibody development. The company aims to improve global healthcare outcomes by providing accessible and affordable diagnostic and therapeutic solutions, with a mission to make their technology available globally to transform the diagnostic sector. They offer a range of services including antibody development, recombinant protein production, and assay development, and have launched products such as Lyme disease diagnostic kits and assays.

EpitogenX is a biotech company developing innovative platforms for immunoassay, vaccine, and antibody development using artificial intelligence. Their core technologies, EpitoGen® and AI EpitoPrediktTM, are designed to revolutionize diagnostics, vaccine design, biotherapeutics, and antibody development. The company aims to improve global healthcare outcomes by providing accessible and affordable diagnostic and therapeutic solutions, with a mission to make their technology available globally to transform the diagnostic sector. They offer a range of services including antibody development, recombinant protein production, and assay development, and have launched products such as Lyme disease diagnostic kits and assays.